Post by Regeneron on X
Regeneron@Regeneron
XToday, a federal jury found that Amgen’s anticompetitive activities prevented Regeneron from competing on a level playing field and unfairly denied patients access to its PCSK9 treatment. This verdict is critical to protecting biotech innovation and patient access to treatments.
49 likes3 repliesPosted May 15, 2025